Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05223335 · ClinicalTrials.gov registry record · Phase 4
Clopidogrel Monotherapy in Patients With High Bleeding Risk
A Phase 4 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 98
- Enrollment target
NCT05223335: Completed Phase 4 study, sponsored by Mayo Clinic.
NCT05223335 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 98 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05223335, a Phase 4 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 98 participants
- Enrollment target
Study Summary
The goal of this research is to show that a shorter duration of two antiplatelet medications (compared to the standard of care) is safe and effective while reducing the risk of bleeding complications. Bleeding complications can cause significant problems (hospitalizations, need for blood transfusions, and even death) for patients on antiplatelet medications after coronary stents. Researchers hope to show that reducing the time on two antiplatelet agents in patients at high risk for these bleeding complications will reduce the number of bleeding events while not causing any increase in cardiovascular complications (heart attack, stent malfunction, death).
Interventions
- DRUG Clopidogrel
- DRUG Prasugrel
- DRUG Tricagrelor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2022-03-29 |
| Est. Completion | 2023-03-16 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05223335
The ClinicalTrials.gov registry entry for NCT05223335 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Clopidogrel is the first listed.
NCT05223335 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05223335 about?
NCT05223335 is a clinical study titled "Clopidogrel Monotherapy in Patients With High Bleeding Risk". The goal of this research is to show that a shorter duration of two antiplatelet medications (compared to the standard of care) is safe and effective while reducing the risk of bleeding complications. Bleeding complications can cause significant problems (hospitalizations, need for blood transfusion...
What is the current status of trial NCT05223335?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 98 participants. The study started on 2022-03-29. Estimated completion is 2023-03-16.
What interventions are being tested in trial NCT05223335?
The interventions under investigation include: Clopidogrel (DRUG), Prasugrel (DRUG), Tricagrelor (DRUG).
Who is sponsoring clinical trial NCT05223335?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.